7 assets in Pancreatic Neuroendocrine Neoplasm

Therapeutic assets addressing Pancreatic Neuroendocrine Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ifa Pancreatic Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)
Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer Pancreatic Neuroendocrine Neoplasm	Fudan University	P2	CCC (53)
Sargramostim Pancreatic Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)
Survaxm Pancreatic Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)
Cabozantinib Pancreatic Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P3	NR ()